IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION

Track this case

Case overview

Case Number:

9:20-md-02924

Court:

Florida Southern

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation, Class Action

Judge:

Robin L. Rosenberg

Firms

Companies

Sectors & Industries:

  1. January 04, 2021

    Zantac Generics MDL Labeling Claims Axed As Preempted

    A Florida federal judge presiding over sprawling multidistrict litigation over the carcinogens found in the popular heartburn medication Zantac has held that state labeling and design defect claims against Zantac generics makers, repackagers, retailers and distributors are preempted by federal law.

  2. December 15, 2020

    Zantac MDL Defendants Argue Claims Are Preempted

    Drugmakers, retailers and distributors targeted in the multidistrict litigation over heartburn medication Zantac told a Florida federal court on Tuesday that plaintiffs' state law claims over alleged design and labeling defects are preempted by federal law.

  3. December 14, 2020

    Drugmakers Call Zantac MDL 'Shotgun Pleadings'

    Drugmakers ensnared in the multidistrict litigation over heartburn medication Zantac rattled off a litany of problems with the plaintiffs' claims to a Florida federal judge on Monday, calling them "shotgun pleadings" that improperly lump together all defendants and fail to allege injury.

  4. May 12, 2020

    Zantac Makers Say Drug Has No Cancer Link As MDL Opens

    Drugmakers caught up in the multidistrict litigation over heartburn medication Zantac told a Florida federal court Tuesday the lawsuits are "based on a series of mights and maybes," saying there's no evidence of a causal link between the drug and cancer.

  5. May 11, 2020

    Younger Attorneys Get Chance At Big Role In Zantac MDL

    A Florida federal judge created a novel leadership structure for the team representing plaintiffs in multidistrict litigation over heartburn medication Zantac in an attempt to give qualified but inexperienced attorneys a chance to play a meaningful role in what is shaping up to be a major MDL in the federal court docket.